NASDAQ:VTVTvTv Therapeutics Stock Price, Forecast & News

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VTVT shares have increased by 21.4% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics.

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for vTv Therapeutics.

vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company earned $0.01 million during the quarter. View vTv Therapeutics' earnings history.

2 equities research analysts have issued 1 year target prices for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect vTv Therapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 137.3% from the stock's current price. View analysts' price targets for vTv Therapeutics.

News coverage about VTVT stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. vTv Therapeutics earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutvTv Therapeutics.

vTv Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,690,000 shares, an increase of 10.5% from the April 30th total of 1,530,000 shares. Based on an average daily volume of 713,400 shares, the short-interest ratio is presently 2.4 days. Approximately 20.1% of the company's stock are sold short. View vTv Therapeutics' Current Options Chain.

Some companies that are related to vTv Therapeutics include Kura Oncology (KURA), Gossamer Bio (GOSS), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), Homology Medicines (FIXX), Kadmon (KDMN), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Molecular Templates (MTEM), G1 Therapeutics (GTHX), Akero Therapeutics (AKRO), Ardelyx (ARDX), ZIOPHARM Oncology (ZIOP) and Morphic (MORF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Opko Health (OPK), Amarin (AMRN), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO) and Trevena (TRVN).

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Frazier Management LLC (1.63%), Two Sigma Investments LP (0.41%), Two Sigma Advisers LP (0.06%), Spark Investment Management LLC (0.04%) and Wedbush Securities Inc. (0.02%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View institutional ownership trends for vTv Therapeutics.

VTVT stock was acquired by a variety of institutional investors in the last quarter, including Frazier Management LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Spark Investment Management LLC, and Wedbush Securities Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas, and Ronald O Perelman. View insider buying and selling activity for vTv Therapeutics.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VTVT stock can currently be purchased for approximately $2.95.

vTv Therapeutics has a market capitalization of $199.93 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.

The official website for vTv Therapeutics is www.vtvtherapeutics.com.

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]